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Abstract
Background: the impact of sarcopenia on quality of life is currently assessed by generic tools. However, these tools may not
detect subtle effects of this speciﬁc condition on quality of life.
Objective: the aim of this study was to develop a sarcopenia-speciﬁc quality of life questionnaire (SarQoL, Sarcopenia Quality
of Life) designed for community-dwelling elderly subjects aged 65 years and older.
Settings: participants were recruited in an outpatient clinic in Liège, Belgium.
Subjects: sarcopenic subjects aged 65 years or older.
Methods: the study was articulated in the following four stages: (i) Item generation—based on literature review, sarcopenic subjects’
opinion, experts’ opinion, focus groups; (ii) Item reduction—based on sarcopenic subjects’ and experts’ preferences; (iii) Questionnaire
generation—developed during an expert meeting; (iv) Pretest of the questionnaire—based on sarcopenic subjects’ opinion.
Results: the ﬁnal version of the questionnaire consists of 55 items translated into 22 questions rated on a 4-point Likert scale.
These items are organised into seven domains of dysfunction: Physical and mental health, Locomotion, Body composition,
Functionality, Activities of daily living, Leisure activities and Fears. In view of the pretest, the SarQoL is easy to complete, inde-
pendently, in10 min.
Conclusions: the ﬁrst version of the SarQoL, a speciﬁc quality of life questionnaire for sarcopenic subjects, has been devel-
oped and has been shown to be comprehensible by the target population. Investigations are now required to test the psycho-
metric properties (internal consistency, test–retest reliability, divergent and convergent validity, discriminant validity, ﬂoor and
ceiling effects) of this questionnaire.
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Introduction
Sarcopenia is deﬁned by a progressive and generalised loss of
muscle mass and function with advancing age [1, 2]. This
geriatric syndrome, now recognised as a major clinical pro-
blem for older people, is an increasing public health issue in
our society [3]. Indeed, sarcopenia is associated with some
adverse clinical outcomes such as physical impairment, limi-
tation of mobility, increased risk of falls, hospitalisation and
mortality [4–8] but also with major co-morbidities such as
type 2 diabetes, obesity and osteoporosis [9].
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As of today, the association between sarcopenia and
altered quality of life (QoL) has been little studied. Health-
related QoL is deﬁned by the World Health Organization
(WHO) as an individual’s perception of their position in life
in the context of the culture and value systems in which they
live and in relation to their goals, expectations, standards and
concerns. Although the decline in HR-QoL is intuitively
evident for sarcopenic subjects, it is only supported by a few
studies showing a signiﬁcant association between, on one
side, decreased grip strength and, on the other side,
decreased physical and general health [10–12]. Moreover,
QoL in these studies has only been measured through
generic QoL questionnaires. However, generic tools may not
be able to detect subtle effects of a speciﬁc condition on
QoL. Consequently, a speciﬁc tool would be necessary to
assess the impact of sarcopenia on QoL. Even if a large
number of disease-speciﬁc QoL questionnaires currently
exist, none are speciﬁc to sarcopenia. In the absence of such
a speciﬁc tool, the ability to clinically characterise QoL in
subjects with sarcopenia, as well as the capacity to assess
changes over time in the QoL of these subjects seems compro-
mised. Complete assessment of the beneﬁts of a therapeutic
intervention should provide evidence of an impact on patients’
HR-QoL.
The aim of this study was to develop a sarcopenia-speciﬁc
QoL questionnaire, called SarQoL (Sarcopenia Quality of
Life), designed for community-dwelling elderly subjects aged
65 years and older. In this paper, we describe the four stages
of the development of this speciﬁc QoL questionnaire.
Methods
Based on different procedures on how to develop a HR-
QoL questionnaire [13–15], but also on experts’ recommen-
dations and on many successful studies [16–20], we applied
the following four steps to develop our questionnaire (Figure 1):
Step 1. Item generation—based on literature review, sarcope-
nic subjects’ opinion, experts’ opinion, focus groups.
Step 2. Item reduction—based on sarcopenic subjects’ and
experts’ relevance ranking.
Step 3. Questionnaire generation—developed during an expert
meeting.
Step 4. Pretest of the questionnaire—based on sarcopenic
subjects’ opinion.
Figure 1.Overview of study procedures.
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Language
The SarQoL questionnaire has been developed in French.
Identification of experts
Different experts (eight from Belgium, one from France and
two from Switzerland) were included in the development of
this questionnaire: three geriatricians (S.G., J.P., Y.R.), three
rheumatologist experts in the ﬁeld of bone and muscle (E.B.,
J.Y.R., R.R.), one physiotherapist and Professor in Bio-
Gerontology and Geriatric Rehabilitation (I.B.), one linguist
expert in the French language ( J.V.B.), two experts in meth-
odology of questionnaires (M.J., P.I.) and, at last, one statisti-
cian (N.D.).
Identification of patient population
We used the deﬁnition of the European Working Group on
Sarcopenia in Older People (EWGSOP) [21] as criteria for
diagnosing sarcopenic subjects. Subjects, aged 65 years and
older, were recruited in an outpatient clinic in Liège, Belgium.
They are currently enrolled in a 5-year prospective Belgian
cohort called SarcoPhAge [22]. Sarcopenia was deﬁned as
follows:
– An appendicular lean muscle mass/height2 (SMI) <5.5
kg/m2 for women and <7.26 kg/m2 for men assessed
by Dual-energy X-ray absorptiometry.
– A muscle strength <20 kg for women and <30 kg for
men assessed by a hydraulic hand dynamometer OR
physical performance: ≤8 points for the Short Physical
Performance Battery (SPPB) test.
Forty-six community-dwelling sarcopenic subjects were
recruited in an outpatient clinic in Liège, Belgium. Inclusion
criteria included age ≥65 years, French maternal language
and written informed consent obtained. Exclusion criteria
were amputated limb and BMI above 30 kg/m2.
Subjects had to read and sign an informed consent after
having been informed of the objectives and methods of the
research. The study was approved by the Ethics Committee
of the University Teaching Hospital of Liège (number 2013/6).
Step 1: Item generation
Items for the SarQoL were generated in a three-step process.
The ﬁrst step was to draw up, from an exhaustive review of
the literature, a comprehensive list of items about QoL in sar-
copenia. This list of items was drawn up not only from
generic QoL questionnaires intended to either a general
population or a population of similar age but also from dif-
ferent studies having assessed the QoL of frail and sarcope-
nic subjects. This list was then amended after having
interviewed ﬁve subjects with sarcopenia, in a face-to-face
discussion, about how sarcopenia impacts their QoL. All
interviews, using open discussion and open-ended questions,
were performed by the same clinical researcher (C.B.).
During these interviews, sarcopenic subjects described all
problems related to sarcopenia that affected their QoL.
Answers were transcribed, and a qualitative content analysis
of the responses was carried out according to the published
methodology [23, 24]. Finally, this list was completed by
feedbacks of experts who had received a semi-structured
questionnaire, which allowed them to discuss about sarcope-
nia and its impact on QoL.
Then, the list of items was discussed with the experts in
a meeting to reformulate some of them, delete or subdivide
others, and, ﬁnally, organise them into domains of dysfunction.
Step 2: Item reduction
The aim of this step was to select the most pertinent items to
include in the ﬁnal questionnaire.
To perform this stage, the list of items identiﬁed in the
generation phase was submitted to 21 sarcopenic subjects,
different from those included in Phase 1, and to the experts.
They had to grade the relevance of each item on a 4-point
Likert scale ranging from ‘1, not relevant’ to ‘4, extremely
relevant’. Then, for each item, we examined its ‘frequency’
(the proportion of subjects or experts who identiﬁed the
item as ‘extremely relevant’) and its importance (the mean
importance score based on the Likert scale for this item) and
selected items on the basis of the product: frequency ×
importance. Redundancy of items was also taken into consid-
eration throughout the item reduction process.
Step 3: Development of the questionnaire SarQoL
A focus group was organised with all experts to translate the
amended list of items into clear, brief, unambiguous and rele-
vant questions. This meeting also served to deﬁne the layout
of the questionnaire, the response format and the scoring al-
gorithm. This ﬁrst version of the questionnaire was submit-
ted to a French linguist to ensure that it was free of any
spelling or linguistic errors.
Step 4: Pretest of the questionnaire SarQoL
Once checked by the linguist, the questionnaire was submit-
ted to a sample of 20 sarcopenic patients, different from
those included in Stage 1 and Stage 2, to ensure the good
understandability of each question and the acceptability of
the questionnaire’s format. Subjects were invited to express
their misunderstanding and to formulate recommendations
over the questions. Following this pretest, the second and
ﬁnal version of the questionnaire SarQoL was established.
Statistical analysis
Patient’s characteristics are described as median (P25–P75)
for continuous variables and count and percentage for cat-
egorical variables.
For item reduction, the impact of each item was calcu-
lated by multiplying the frequency of an item by its mean im-
portance. This calculation was performed for subjects and
for experts separately. The items with an impact of ≥0.5
both for subjects and for experts were selected. Other items
were excluded from the list.
All analyses were executed with the software Statistica 9.1.
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Results
Patient population
A total of 46 sarcopenic subjects were included in the devel-
opment of the questionnaire. 78.3% of subjects were women
with a mean age of 76.3 ± 6.51 years. Five sarcopenic sub-
jects were included in the phase of items generation, 21 sar-
copenic subjects participated in the phase of items reduction
and 20 for the pretest. Subjects’ characteristics are given in
Table 1.
Step 1: Item generation
From the literature review, a ﬁrst list of 67 items was drawn
up. After complementing this list with the open interviews of
ﬁve sarcopenic subjects and the feedback from the semi-
structured questionnaires sent to seven experts (E.B., I.B.,
S.G., J.P., R.R., J.Y.R., Y.R.), a new list of 180 items was gener-
ated. A meeting was then held with all the experts to discuss
on the basis of this 180-item list which items had to be
deleted because of redundancy, similarity or repetition and
which items had to be combined or reformulated. These
decisions were made on the basis of consensus agreement
between the research team and the experts. At the end of the
meeting, the list was reduced to 136 items, structured into
eight domains: Physical and Mental Health, Locomotion,
Social relations, Body composition, Functionality, Activities
of daily living, Leisure activities and Fears.
Step 2: Item reduction
The 136-item list was given to 21 subjects diagnosed sarco-
penic and to the experts. Only the items with a frequency ×
importance product of 0.5 or greater were retained. In three
domains, Social relation, Body composition and Fears, no
item reached this cut-off point. At this stage, the process
reduced the number of items to 48, classiﬁed into ﬁve
domains. Consensus agreement between experts was to keep
three items from the domain of Body composition and four
items from the domain of Fears and to remove the domain
of Social relation from the questionnaire because of its very
low score from both patients and experts. The decision of
keeping items from the Body composition and Fears
domains was based on the fact that the mean rating for these
items was >1 for either the experts or the subjects. Following
this consensual decision of experts, a ﬁnal list of 55 items,
classiﬁed into seven domains was achieved (Table 2).
Step 3: Development of the questionnaire SarQoL
The 55 items were translated into 22 questions during a
meeting organised with the experts. The decision regarding
the format of questions was made by general consent of the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1.Demographic and clinical characteristics of patients involved in Phase 1, Phase 2 and Phase 4 of the development
Phase 1: Item generation (n= 5) Phase 2: Item reduction (n= 21) Phase 4: Pretest (n= 20)
Age 73.0 (71.0–79.0) 76.1 (71.6–80.1) 75.1 (71.7–80.0)
Sex
Women 5 (100.0) 13 (61.9) 18 (90.0)
Anthropometric data
Height (cm) 161.4 (161.0–166.7) 161.3 (156.7–168.1) 157.5 (152.7–162.0)
Weight (kg) 60.3 (50.0–67.5) 58.3 (53.5–61.8) 60.0 (55.2–66.2)
BMI (kg/m2) 23.1 (17.9–26.0) 22.2 (20.6–23.7) 23.8 (23.2–26.9)
Calf circumference (cm) 33.5 (28.0–33.5) 31.0 (29.5–32.0) 32.0 (30.0–34.2)
Wrist circumference (cm) 15.0 (15.0–15.5) 16.0 (15.0–17.0) 15.5 (15.0–16.5)
Arm circumference (cm) 26.0 (25.0–26.0) 24.5 (23.0–27.0) 26.7 (24.7–27.7)
Civil status
Married 2 (40.0) 12 (57.1) 12 (60.0)
Divorced 2 (40.0) 3 (14.3) 17 (10.0)
Widow 1 (20.0) 4 (19.0) 4 (20.0)
Single 0 (0.00) 2 (9.52) 2 (10.0)
Level of education
Without qualification 0 (0.00) 0 (0.00) 0 (0.00)
Primary school 3 (60.0) 2 (9.52) 2 (10.0)
Secondary school 2 (40.0) 11 (52.4) 10 (50.0)
Post-secondary education 0 (0.00) 8 (38.1) 8 (40.0)
Number of diseases 2.0 (2.0–7.0) 5.0 (4.0–8.0) 4.5 (3.0–6.0)
Number of drugs 8.0 (7.0–9.0) 6.0 (5.0–9.0) 6.0 (5.0–10.0)
Gait speed (m/s) 0.95 (0.79–0.97) 0.94 (0.77–1.18) 0.88 (0.78–1.01)
Grip strength maximum (kg)
Women 24.6 (20.1–25.3) 19.5 (16.0–22.0) 18.0 (16.0–20.5)
Men – 27.0 (21.5–29.5) 41.7 (38.0–45.5)
SMI (kg/m2)
Women 4.97 (4.8–5.3) 5.07 (4.68–5.35) 5.31 (4.76–5.46)
Men – 6.43 (6.21–6.60) 7.15 (7.10–7.25)
SMI, skeletal muscle index (appendicular lean mass/height2).
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experts after discussion. The experts proposed a 4-point
Likert scale of frequency (often, sometimes, rarely, never) or
intensity (a lot, moderately, a bit, not at all) for all questions
at the exception of one question. Seven questions were
displayed in a table including several items, and other ques-
tions were displayed as unique questions. No question uses a
recall period. The total scoring of the SaQoL questionnaire
ranges from 0 (worst imaginable health) to 100 (best imagin-
able health). At this stage, the ﬁrst version of the SarQoL
questionnaire was established.
Step 4: Pretest of the questionnaire SarQoL
Finally, the SarQoL questionnaire was pretested on a group
of 20 sarcopenic subjects. It took 10 min to patients to
self-administer the questionnaire. No patient reported any
difﬁculty in completing the questionnaire or interpreting the
questions. The questionnaire was consequently kept unchanged.
Discussion
In the present study, we report the development of the ﬁrst
speciﬁc, self-administrated sarcopenia-related QoL question-
naire, the SarQoL questionnaire. This questionnaire includes
55 items translated into 22 questions rated on a 4-point
Likert scale. In view of the pretest, the SarQoL is easy to
complete, independently, in10 min.
Sarcopenia is associated with the development of physical
disability, with nursing home admission, depression, hospi-
talisation, many co-morbidities, poor physical performance,
functional decline, falls and with short- and long-term mor-
tality in hospitalised patients [3]. However, as of today, few
studies have assessed the impact of sarcopenia on QoL. In
2012, Kull et al. [11] found a reduced QoL in two domains
(i.e. physical function and vitality) of the SF-36 questionnaire
in sarcopenic subjects. Two other studies found that sarcope-
nic subjects presented poorer general health and physical
functioning scores [12] and presented signiﬁcantly more pro-
blems of mobility, self-care, usual activity and anxiety than
non-sarcopenic subjects [25]. Other studies showed an
indirect association between sarcopenia and QoL with a sig-
niﬁcant correlation between reduced grip strength, one of
the components of sarcopenia, and reduced QoL in the
domains of physical functioning and general health [10, 26].
Another study also showed a correlation between reduced
muscle mass in men and reduced general health, assessed
with the SF-36 questionnaire [27]. All these results highlight
the fact that QoL of subjects suffering from sarcopenia is
affected only in speciﬁc domains. Even if the SF-36 is widely
in use, simple and effective [28], it is acknowledged that
this generic tool should be supplemented with disease-
speciﬁc instruments [29]. There is a need of a speciﬁc QoL
questionnaire in the ﬁeld of sarcopenia [8]. This question-
naire should include the physical aspects of the musculoskel-
etal domains but should also give an even-handed balance to
other factors affecting QoL. During the development of
the SarQoL, we followed carefully these recommendations
and included therefore no less than seven domains of dys-
function: Physical and Mental Health, Locomotion, Body
composition, Functionality, Activities of daily living, Leisure
activities and Fears.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Presentation of the final 55 items composing the
SarQoL questionnaire
Domains Items
Physical and mental health Loss of arm strength
Loss of leg strength
Loss of energy
Muscle pain
Feeling of muscle weakness
Feeling of being frail
Feeling old
Feeling of being physically weak
Locomotion Limitation in walking time
Limitation in number of outings outdoor
Limitation in walking distance
Limitation in walking speed
Limitation in steps length
Feeling of fatigue when walking
Need of recovery time when walking
Difficulties to cross a road fast enough
Difficulties to walk on uneven grounds
Body composition Physical change
Loss of muscle mass
Weight change (loss or gain)
Functionality Balance problems
Falls occurrence
Loss of physical capacity
Loss of flexibility
Climbing one flight of stairs
Climbing several flight of stairs
Climbing stairs without a banister
Stooping
Crouching or kneeling
To stand from a sitting position
Get up from a chair
To stand up from the floor without any support
Limitation of movement
Sexuality
Activities of daily living Difficulty during light physical effort
Fatigue during light physical effort
Pain during light physical effort
Difficulty during moderate physical effort
Fatigue during moderate physical effort
Pain during moderate physical effort
Difficulty during intensive physical effort
Fatigue during intensive physical effort
Pain during intensive physical effort
Shopping
Household tasks
Carrying heavy objects
Open a bottle or a jar
Take public transportation
To get in/out a car
Leisure activities Change in physical activities
Change in leisure activities
Fears Fear of getting hurt
Fear of not succeeding
Fear of being tired
Fear of falling
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HR-QoL assessments are obviously important for
healthcare providers and regulatory agencies to understand
the needs and preoccupation of important segments of
the population, such as elderly subjects suffering from
sarcopenia. Such a tool could enhance the accuracy of
assessments of well-being and physical function, psy-
chological and social implications of sarcopenic subjects.
With the future expected development of interventions tar-
geting sarcopenia, this tool will also be useful to measure
the effectiveness and relevance of these new therapeutic
strategies.
Our study presents several strengths. First of all, we
respected guidelines and followed rigorous steps, which have
previously been successfully used in many other studies.
Next, many experts have been actively involved in the devel-
opment process; eight clinician experts in the ﬁeld of sarco-
penia, one linguist expert in the French language, two experts
in the methodology of questionnaires and one statistician.
This large and heterogeneous panel of experts ensured a
rigorous methodology, a good use of the French language
throughout the questionnaire and a content validity. Moreover,
the content validity was also provided by the large range of
sources used to generate items and by the inclusion of sarco-
penic patients in the two ﬁrst stages of the development of
the questionnaire, the item generation and the reduction of
items. Some weaknesses could however be pointed out. First
of all, the inclusion of 46 subjects in the development process
could be considered as too limited but is in line with the
methodology used in other studies [30, 31]. Secondly, these
subjects are also enrolled in another study on sarcopenia (the
SarcoPhAge study [22]) and might, consequently, be more
aware of the impact of sarcopenia given the participant’s in-
formation and assessments they underwent for the prospect-
ive study. We must also note that the majority of the sample
is composed of women, which could have some impact
on the results. Moreover, in the item generation phase, all
included subjects were women. However, the inclusion of
subjects in this phase is not formally requested and only
ensures a content validity to the questionnaire. Anyway, we
acknowledge that if some men would have been included in
this phase, it might have resulted in having some items more
speciﬁc to men added to the list of items generated. Another
limitation is that the questionnaire has only been developed
with ambulatory community-dwelling subjects and could not
be fully adapted to other populations. Finally, only French-
speaking subjects were studied, and characteristics of French-
speaking Belgian sarcopenic subjects could differ from subjects
from other countries.
Future works
Even if the SarQoL questionnaire is now developed, this
questionnaire is not yet ready to be used. Indeed, veriﬁcation
of psychometric properties has still to be done and is cur-
rently on the way. Future work includes ﬁrst the development
of a scoring algorithm and a factorial analysis of the included
questions; second, the analysis of the convergent and diver-
gent validity of the questionnaire, the internal consistency,
the test–retest reliability, and the potential ceiling and ﬂoor
effects.
Key points
• The generic quality of life tools may not detect subtle
effects of sarcopenia on quality of life.
• A ﬁrst version of the SarQoL, a speciﬁc quality of life ques-
tionnaire for sarcopenic subjects, has been developed.
• The SarQoL has been shown to be comprehensible by the
target population.
• Investigations are now required to test the psychometric
properties of this questionnaire.
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